Bioniq, founded in 2019 and headquartered in the United Kingdom, is carving a niche in the Health Care, Health and Wellness, and Sports industries with its commitment to personalized health solutions.
The company operates on the forefront of health tech innovation, utilizing a proprietary biochemical database and patented technology to offer tailored health optimization solutions. Emphasizing scientific backing, Bioniq has earned recommendations from world-leading medical institutions, aligning with its slogan: "Your ultimate personalized supplements. Clinically proven and backed by science."
The company recently secured a $15.00M Series B investment on 16 July 2024 from notable investors such as HV Capital and Unbound. This funding round signifies increased confidence in Bioniq's strategic vision and potential to revolutionize personalized health, making it an attractive prospect for forward-thinking investors.